These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 10336801)

  • 41. Small sample approach, and statistical and epidemiological aspects.
    Offringa M; van der Lee H
    Handb Exp Pharmacol; 2011; 205():181-202. PubMed ID: 21882112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sample size and optimal designs in stratified comparative trials to establish the equivalence of treatment effects among two ethnic groups.
    Chen YH; Wang M
    J Biopharm Stat; 2002 Nov; 12(4):553-66. PubMed ID: 12477074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calculation of sample size in survival trials: the impact of informative noncompliance.
    Jiang Q; Snapinn S; Iglewicz B
    Biometrics; 2004 Sep; 60(3):800-6. PubMed ID: 15339304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
    Kikuchi T; Gittins J
    Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Aspects of sample size determination and power calculation illustrated on examples from rehabilitation research].
    Kutschmann M; Bender R; Grouven U; Berg G
    Rehabilitation (Stuttg); 2006 Dec; 45(6):377-84. PubMed ID: 17123220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal two-stage designs for clinical trials based on safety and efficacy.
    Thall PF; Cheng SC
    Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mid-course sample size modification in clinical trials based on the observed treatment effect.
    Jennison C; Turnbull BW
    Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sample size calculations: basic principles and common pitfalls.
    Noordzij M; Tripepi G; Dekker FW; Zoccali C; Tanck MW; Jager KJ
    Nephrol Dial Transplant; 2010 May; 25(5):1388-93. PubMed ID: 20067907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
    Fazzari M; Heller G; Scher HI
    Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. On the choice of doses for phase III clinical trials.
    Lisovskaja V; Burman CF
    Stat Med; 2013 May; 32(10):1661-76. PubMed ID: 23023767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sample size estimation: a glimpse beyond simple formulas.
    Eng J
    Radiology; 2004 Mar; 230(3):606-12. PubMed ID: 14990827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sample size for comparing linear growth curves.
    Patel HI; Rowe E
    J Biopharm Stat; 1999 May; 9(2):339-50. PubMed ID: 10379697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.